

Epiomic Epidemiology Series: Mucopolysaccharidosis-III (MPS-III) Sanfilippo Syndrome Forecast in 23 Major Markets 2017-2027

<https://marketpublishers.com/r/E107408A7B7EN.html>

Date: January 2017

Pages: 74

Price: US\$ 6,150.00 (Single User License)

ID: E107408A7B7EN

Abstracts

Mucopolysaccharidosis-III, also known as MPS-III or Sanfilippo syndrome, is part of the Mucopolysaccharidoses (MPS) disorders - a group of rare genetic disorders caused by deficiencies of lysosomal enzymes. These are in-born errors of metabolism, and are autosomal recessive genetic disorders.

There are 4 distinct sub-types of MPS-III (A, B, C & D), with patients ranging from mild to severe in terms of symptoms. Prevalence of the different subtypes varies markedly country to country.

This report provides the current prevalent population for MPS-III across 23 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Australia, Netherlands, Denmark, Sweden, Norway, Turkey, Greece, Portugal, Poland, Estonia, Russia, Czech Republic) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of MPS-III have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for MPS-III disease include:

Hernia

Hearing loss and otitis

Sleep disorders

Neurological and behavioural disorders

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Able to quantify patient populations in global MPS-III market to target the development of future products, pricing strategies and launch plans.

Gain further insight into the prevalence of the subdivided types of MPS-III and identify patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Provide a level of understanding on the impact from specific co-morbid conditions on MPS-III prevalent population.

Identify sub-populations within MPS-III which require treatment.

Gain an understanding of the specific markets that have the largest number of MPS-III patients.

Contents

- Introduction
- Cause of the Disease
- Risk Factors & Prevention
- Diagnosis of the Disease
- Variation by Geography/Ethnicity
- Disease Prognosis & Clinical Course
- Key comorbid conditions/Features associated with the disease
- Methodology for quantification of patient numbers
- Top-line prevalence for MPS-III
 - Main Subtype
- Features of MPS-III patients
- Abbreviations used in the report
- Other Black Swan Analysis Publications
- Black Swan Analysis Online Patient-Based Databases
- Patient-Based Offering
- Online Pricing Data and Platforms
- References
- Appendix

List Of Tables

LIST OF TABLES

Prevalence of MPS-III, total (000s)
Prevalence of MPS-III, males (000s)
Prevalence of MPS-III, females (000s)
MPS-III patients by Sub-type, total (000s)
MPS-III patients with coarse features, total (000s)
MPS-III patients with Hepatomegaly, total (000s)
MPS-III patients with language delay, total (000s)
MPS-III patients with Abnormal behaviour, total (000s)
MPS-III patients with ASD, total (000s)
MPS-III patients with epilepsy, total (000s)
Abbreviations and Acronyms used in the report
USA Prevalence of MPS-III by 5-yr age cohort, males (000s)
USA Prevalence of MPS-III by 5-yr age cohort, females (000s)
Canada Prevalence of MPS-III by 5-yr age cohort, males (000s)
Canada Prevalence of MPS-III by 5-yr age cohort, females (000s)
France Prevalence of MPS-III by 5-yr age cohort, males (000s)
France Prevalence of MPS-III by 5-yr age cohort, females (000s)
Germany Prevalence of MPS-III by 5-yr age cohort, males (000s)
Germany Prevalence of MPS-III by 5-yr age cohort, females (000s)
Italy Prevalence of MPS-III by 5-yr age cohort, males (000s)
Italy Prevalence of MPS-III by 5-yr age cohort, females (000s)
Spain Prevalence of MPS-III by 5-yr age cohort, males (000s)
Spain Prevalence of MPS-III by 5-yr age cohort, females (000s)
UK Prevalence of MPS-III by 5-yr age cohort, males (000s)
UK Prevalence of MPS-III by 5-yr age cohort, females (000s)
Brazil Prevalence of MPS-III by 5-yr age cohort, males (000s)
Brazil Prevalence of MPS-III by 5-yr age cohort, females (000s)
Japan Prevalence of MPS-III by 5-yr age cohort, males (000s)
Japan Prevalence of MPS-III by 5-yr age cohort, females (000s)
India Prevalence of MPS-III by 5-yr age cohort, males (000s)
India Prevalence of MPS-III by 5-yr age cohort, females (000s)
China Prevalence of MPS-III by 5-yr age cohort, males (000s)
China Prevalence of MPS-III by 5-yr age cohort, females (000s)
Russia Prevalence of MPS-III by 5-yr age cohort, males (000s)
Russia Prevalence of MPS-III by 5-yr age cohort, females (000s)

Australia Prevalence of MPS-III by 5-yr age cohort, males (000s)
Australia Prevalence of MPS-III by 5-yr age cohort, females (000s)
Netherlands Prevalence of MPS-III by 5-yr age cohort, males (000s)
Netherlands Prevalence of MPS-III by 5-yr age cohort, females (000s)
Denmark Prevalence of MPS-III by 5-yr age cohort, males (000s)
Denmark Prevalence of MPS-III by 5-yr age cohort, females (000s)
Sweden Prevalence of MPS-III by 5-yr age cohort, males (000s)
Sweden Prevalence of MPS-III by 5-yr age cohort, females (000s)
Norway Prevalence of MPS-III by 5-yr age cohort, males (000s)
Norway Prevalence of MPS-III by 5-yr age cohort, females (000s)
Turkey Prevalence of MPS-III by 5-yr age cohort, males (000s)
Turkey Prevalence of MPS-III by 5-yr age cohort, females (000s)
Greece Prevalence of MPS-III by 5-yr age cohort, males (000s)
Greece Prevalence of MPS-III by 5-yr age cohort, females (000s)
Portugal Prevalence of MPS-III by 5-yr age cohort, males (000s)
Portugal Prevalence of MPS-III by 5-yr age cohort, females (000s)
Poland Prevalence of MPS-III by 5-yr age cohort, males (000s)
Poland Prevalence of MPS-III by 5-yr age cohort, females (000s)
Estonia Prevalence of MPS-III by 5-yr age cohort, males (000s)
Estonia Prevalence of MPS-III by 5-yr age cohort, females (000s)
Czech Republic Prevalence of MPS-III by 5-yr age cohort, males (000s)
Czech Republic Prevalence of MPS-III by 5-yr age cohort, females (000s)

I would like to order

Product name: Epiomic Epidemiology Series: Mucopolysaccharidosis-III (MPS-III) Sanfilippo Syndrome Forecast in 23 Major Markets 2017-2027

Product link: <https://marketpublishers.com/r/E107408A7B7EN.html>

Price: US\$ 6,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E107408A7B7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

